

SUPPLEMENTARY INFORMATION

Kodahl AR *et al.* Correlation between circulating cell-free *PIK3CA* tumor DNA levels and treatment response in patients with *PIK3CA*-mutated metastatic breast cancer.

Table S1. Level of detection and level of blank of the ddPCR assay. From non-mutated serum samples the level of detection (LoD) was calculated based on the level of blanks (LoB) from pre-amplified cell-free plasma DNA using the Q5 High-Fidelity DNA Polymerase (New England BioLabs).

	E542K	E545K	H1047R	H1047L
LoB (%)	0.024	0.024	0.039	0.005
Std.dev. (%)	0.0097	0.0136	0.0188	0.0046
LoD (%) (95% confidence)	0.0435	0.0513	0.0763	0.0141
n	40	34	26	33




Figure S1. Overall survival analysis of patients analyzed for circulating cell-free *PIK3CA* mutations in serum. Kaplan-Meier curves illustrates overall survival of metastatic breast cancer patients with *PIK3CA* mutation and wild type (n=29). Median overall survival for all patients were 20 months.